Skip to main content
. 2022 Oct 26;11(21):6314. doi: 10.3390/jcm11216314

Table 10.

Mean (%) change from baseline in the multiple ascending dose regimen of fesomersen. Data are from Liu, Q. et al. [36].

FXI Antigen Reduction FXI Activity Reduction aPTT Prolongation
Placebo (pooled, n = 9) 3 3 1
Fesomersen 50 mg (n = 9) 31 (p = 0.0013) 15 (p = 0.1) 8 (p = 0.14)
Fesomersen 100 mg (n = 9) 54 (p < 0.0001) 45 (p < 0.0001) 18 (p = 0.0078)
Fesomersen 200 mg (n = 9) 78 (p < 0.0001) 71 (p < 0.0001) 67 (p < 0.0001)